{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/management/postpartum-follow-up/","result":{"pageContext":{"chapter":{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up","depth":2,"htmlHeader":"<!-- begin field be76d073-5c2e-446b-abbf-7013282be893 --><h2>Scenario: Postpartum follow-up for hypertensive disorders in pregnancy</h2><!-- end field be76d073-5c2e-446b-abbf-7013282be893 -->","summary":"Covers the assessment and management of women in the postpartum period who have chronic hypertension, gestational hypertension, or pre-eclampsia. There are also sections on the identification and management of postpartum pre-eclampsia/eclampsia, and on breastfeeding and antihypertensive drugs.","htmlStringContent":"<!-- begin item a19d00a3-2a80-47d6-8476-741178eee752 --><!-- begin field 90553f52-da03-4330-9d12-acbc01598203 --><p>From age 13 years onwards (Female).</p><!-- end field 90553f52-da03-4330-9d12-acbc01598203 --><!-- end item a19d00a3-2a80-47d6-8476-741178eee752 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5200912a-a553-5474-9a96-2f17a6ba5524","slug":"follow-up-for-pre-eclampsia","fullItemName":"Follow-up for pre-eclampsia","depth":3,"htmlHeader":"<!-- begin field c7d6c115-71b5-4dc5-93fd-6ff08d4125a3 --><h3>How should I follow up a woman with confirmed pre-eclampsia postpartum?</h3><!-- end field c7d6c115-71b5-4dc5-93fd-6ff08d4125a3 -->","summary":null,"htmlStringContent":"<!-- begin item 402ed0c0-52b9-42fa-b76f-a89ce0f099e6 --><!-- begin field 632d67f4-a8c7-49a5-87b3-b5394ff2d8ba --><ul><li><strong>Women with pre-eclampsia should be transferred to primary care only if:</strong><ul><li>There are no symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a>.</li><li>Blood pressure with or without treatment is 150/100 mmHg or lower.</li><li>Blood test results are stable or improving.</li></ul></li><li><strong>Women should be given an individual care plan on hospital discharge that includes:</strong><ul><li>Who will provide follow-up care, including medical review if needed.</li><li>Frequency of blood pressure monitoring.</li><li>Thresholds for reducing or stopping treatment.</li><li>Indications for referral to primary care for blood pressure review</li><li>Advice on self-monitoring for symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a>.</li></ul></li><li><strong>All women with pre-eclampsia:</strong><ul><li>Should be assessed for symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a>  (particularly severe headache and epigastric pain) at each consultation.</li><li>Who are discharged to primary care with abnormal blood results should have repeat blood tests to measure platelet count, transaminases, and serum creatinine as clinically indicated, until results return to normal.</li></ul></li><li><strong>Women with pre-eclampsia who did not take antihypertensive treatment:</strong><ul><li>Should have their blood pressure measured at least once between days 3–5 after birth. If blood pressure is abnormal, it should then be measured on alternate days until it normalizes.</li><li>Target blood pressure is lower than 140/90 mmHg.</li><li>Antihypertensive treatment should be started if blood pressure is 150/100 mmHg or higher.</li></ul></li><li><strong>Women with pre-eclampsia who took antihypertensive treatment:</strong><ul><li>Should continue receiving antihypertensive treatment.</li><li>Should have their blood pressure measured every 1–2 days for up to 2 weeks after transfer to community, care until treatment is no longer required and there is no hypertension.<ul><li>If blood pressure falls below 140/90 mmHg — a reduction in treatment can be considered.</li><li>If blood pressure falls below 130/80 mmHg — treatment can be reduced.</li></ul></li></ul></li><li><strong>If antihypertensive treatment is required in the postnatal period:</strong><ul><li>Be aware that methyldopa taken during pregnancy should ideally be stopped within 2 days of birth as it may increase the risk of depression.</li><li>For women who are not breastfeeding or planning to breastfeed, hypertension should be managed as for a member of the general population. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>If the woman wishes to breastfeed, enalapril should be offered first-line, with appropriate monitoring of maternal renal function and maternal serum potassium.</li><li>If the woman is of black African or Caribbean family origin, first-line treatment with nifedipine (or amlodipine if the woman has previously used this sucessfully) should be considered.</li><li>Where possible, use of diuretics or angiotensin receptor blockers should be avoided in women who are breastfeeding or expressing milk.</li><li>If blood pressure is not controlled with a single medicine, a combination of nifedipine (or amlodipine) and enalapril can be considered. If this combination is not tolerated or is ineffective, it may be appropriate to either add atenolol or labetalol to the combination treatment <em>or </em>swap one of the medicines being used for atenolol or labetalol. Seek specialist advice where there is uncertainty.</li><li>When treating women with antihypertensive medication during the postnatal period, medicines that are taken once daily should be used wherever possible.</li><li>As antihypertensives can pass (in small quantities) into breastmilk, women who are breastfeeding should be advised to monitor their babies for symptoms of hypotension, such as drowsiness, lethargy, pallor, cold peripheries, or poor feeding.</li></ul></li><li><strong>Women remaining on antihypertensive treatment should be offered a medical review in primary care or with a specialist 2 weeks after transfer to community care.</strong></li><li><strong>A postnatal review 6–8 weeks after birth should be carried out in primary care or by a specialist:</strong><ul><li>All women who have had pre-eclampsia should undergo medical review of their hypertension.</li><li>A urinary reagent-strip test should be carried out. Women with [1+] proteinuria should be offered a further review in primary care or by a specialist three months after delivery to assess kidney function.<ul><li>If this review takes place in primary care, consider referring women with abnormal kidney function at three months postpartum for specialist kidney assessment. Note: the requirement for this will depend largely upon the urinary albumin:creatinine ratio.<strong> </strong> For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>.</li></ul></li></ul></li></ul><!-- end field 632d67f4-a8c7-49a5-87b3-b5394ff2d8ba --><!-- end item 402ed0c0-52b9-42fa-b76f-a89ce0f099e6 -->","subChapters":[{"id":"9bce2d9e-1cbe-56c7-ad44-81979c85fee4","slug":"basis-for-recommendation-794","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f96a1e26-5cfa-4977-880c-901633400c5d --><h4>Basis for recommendation</h4><!-- end field f96a1e26-5cfa-4977-880c-901633400c5d -->","summary":null,"htmlStringContent":"<!-- begin item 794604fc-90e7-4edc-af0f-68b7f862e504 --><!-- begin field 48a1d171-ae6c-454c-bfda-30334258eb8c --><p>The recommendations on postpartum follow-up of women with pre-eclampsia are based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</p><!-- end field 48a1d171-ae6c-454c-bfda-30334258eb8c --><!-- end item 794604fc-90e7-4edc-af0f-68b7f862e504 -->","subChapters":[]}]},{"id":"c6257058-8102-5e54-82fe-df38e205c05b","slug":"follow-up-for-chronic-hypertension","fullItemName":"Follow-up for chronic hypertension","depth":3,"htmlHeader":"<!-- begin field ff4c21c0-9e84-4522-9f12-b6e86ae097db --><h3>How should I follow up a woman with chronic hypertension postpartum?</h3><!-- end field ff4c21c0-9e84-4522-9f12-b6e86ae097db -->","summary":null,"htmlStringContent":"<!-- begin item d144a046-beac-49f3-9897-f2f3e00b8d4b --><!-- begin field 05ad5662-95e2-4ab5-a68b-fa0f2b6e0081 --><ul><li><strong>Note: antihypertensive treatment in the postnatal period will usually be initiated by a specialist before the woman is discharged from hospital. Further monitoring and management may take place in primary care under the terms of a shared-care arrangement.</strong></li><li><strong>Measure blood pressure (this will usually be done by the community midwife after hospital discharge):</strong><ul><li>Daily for the first 2 days postnatally.</li><li>At least once between days 3–5 postnatally.</li><li>As clinically indicated if the woman's antihypertensive treatment is changed postnatally.</li></ul></li><li><strong>Continue antihypertensive treatment if required:</strong><ul><li>Aim to keep blood pressure lower than 140/90 mmHg.</li><li>Be aware that methyldopa taken during pregnancy should ideally be stopped within 2 days of birth as it may increase the risk of depression.</li><li>For women who are not breastfeeding or planning to breastfeed, hypertension should be managed as for a member of the general population. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>If the woman wishes to breastfeed, enalapril should be offered first-line, with appropriate monitoring of maternal renal function and maternal serum potassium.</li><li>If the woman is of black African or Caribbean family origin, first-line treatment with nifedipine (or amlodipine if the woman has previously used this sucessfully) should be considered.</li><li>Where possible, use of diuretics or angiotensin receptor blockers should be avoided in women who are breastfeeding or expressing milk.</li><li>If blood pressure is not controlled with a single medicine, consider a combination of nifedipine (or amlodipine) and enalapril. If this combination is not tolerated or is ineffective, consider either adding atenolol or labetalol to the combination treatment <em>or </em>swapping one of the medicines being used for atenolol or labetalol. Seek specialist advice where there is uncertainty.</li><li>When treating women with antihypertensive medication during the postnatal period, medicines that are taken once daily should be used wherever possible.</li><li>As antihypertensives can pass (in small quantities) into breastmilk, women who are breastfeeding should be advised to monitor their babies for symptoms of hypotension, such as drowsiness, lethargy, pallor, cold peripheries, or poor feeding.</li><li>Reduce antihypertensive treatment if blood pressure falls below 130/80 mmHg<strong>.</strong></li></ul></li><li><strong>Review antihypertensive treatment 2 weeks postnatally.</strong></li><li><strong>Ensure that women with chronic hypertension are offered a medical review 6–8 weeks after the birth either in primary care, or with a specialist as appropriate. </strong></li></ul><!-- end field 05ad5662-95e2-4ab5-a68b-fa0f2b6e0081 --><!-- end item d144a046-beac-49f3-9897-f2f3e00b8d4b -->","subChapters":[{"id":"54fd02d0-1ca8-52e2-ae47-c36b85f56499","slug":"basis-for-recommendation-216","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7f87fcbd-5f41-4728-bf2a-58d596c2c395 --><h4>Basis for recommendation</h4><!-- end field 7f87fcbd-5f41-4728-bf2a-58d596c2c395 -->","summary":null,"htmlStringContent":"<!-- begin item 216c22c2-ede9-4ebd-9a9e-03f84239ef32 --><!-- begin field 3127c425-2475-4dce-a80b-b3996d3d1ebb --><p>The recommendations on postpartum follow-up of women with chronic hypertension are based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</p><!-- end field 3127c425-2475-4dce-a80b-b3996d3d1ebb --><!-- end item 216c22c2-ede9-4ebd-9a9e-03f84239ef32 -->","subChapters":[]}]},{"id":"55b519f5-b60f-5416-8dff-1546121a0cf8","slug":"follow-up-for-gestational-hypertension","fullItemName":"Follow-up for gestational hypertension","depth":3,"htmlHeader":"<!-- begin field 37126c57-2a49-4391-9a39-129e43065860 --><h3>How should I follow up a woman with gestational hypertension postpartum?</h3><!-- end field 37126c57-2a49-4391-9a39-129e43065860 -->","summary":null,"htmlStringContent":"<!-- begin item 12feded0-b61a-4c69-a568-3c4ba807eb28 --><!-- begin field d3aa78d6-dc08-40f3-a0e0-30a301959a43 --><ul><li><strong>Most women with gestational hypertension will be followed up by the maternity unit after delivery until their blood pressure has returned to normal, or will be referred to a specialist if blood pressure remains elevated. W</strong><strong>omen then being transferred to community care should receive a care plan which outlines:</strong><ul><li>Who will provide follow-up care, including medical review if needed.</li><li>Frequency of blood pressure monitoring.</li><li>Thresholds for reducing or stopping treatment.</li><li>Indications for referral to primary care for blood pressure review.</li></ul></li><li><strong>The woman's blood pressure should be measured:</strong><ul><li>Daily for the first 2 days postnatally.</li><li>At least once between days 3–5 postnatally.</li><li>As clinically indicated if the woman's antihypertensive treatment is changed postnatally.</li></ul></li><li><strong>If continued antihypertensive treatment is required:</strong><ul><li>Target blood pressure is lower than 140/90 mmHg.</li><li>Be aware that methyldopa taken during pregnancy should ideally be stopped within 2 days of birth as it may increase the risk of depression.</li><li>For women who are not breastfeeding or planning to breastfeed, hypertension should be managed as for a member of the general population. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>If the woman wishes to breastfeed, enalapril should be offered first-line, with appropriate monitoring of maternal renal function and maternal serum potassium.</li><li>If the woman is of black African or Caribbean family origin, first-line treatment with nifedipine (or amlodipine if the woman has previously used this sucessfully) should be considered.</li><li>Where possible, use of diuretics or angiotensin receptor blockers should be avoided in women who are breastfeeding or expressing milk.</li><li>If blood pressure is not controlled with a single medicine, consider a combination of nifedipine (or amlodipine) and enalapril. If this combination is not tolerated or is ineffective, consider either adding atenolol or labetalol to the combination treatment <em>or </em>swapping one of the medicines being used for atenolol or labetalol. Seek specialist advice where there is uncertainty.</li><li>When treating women with antihypertensive medication during the postnatal period, medicines that are taken once daily should be used wherever possible.</li><li>As antihypertensives can pass (in small quantities) into breastmilk, women who are breastfeeding should be advised to monitor their babies for symptoms of hypotension, such as drowsiness, lethargy, pallor, cold peripheries, or poor feeding.</li><li>Reduce antihypertensive treatment if blood pressure falls below 130/80 mmHg<strong>.</strong></li></ul></li><li><strong>For women with gestational hypertension who did not take antihypertensive treatment and have given birth, antihypertensive treatment should be started if blood pressure is 150/100 mmHg or higher.</strong></li><li><strong>Women who remain on antihypertensive treatment postnatally should  be offered </strong><strong>a medical review in primary care, or with their specialist 2 weeks after transfer to community care.</strong></li><li><strong>Ensure that women with gestational hypertension are offered a medical review 6–8 weeks after the birth either in primary care, or with a specialist as appropriate. </strong></li></ul><!-- end field d3aa78d6-dc08-40f3-a0e0-30a301959a43 --><!-- end item 12feded0-b61a-4c69-a568-3c4ba807eb28 -->","subChapters":[{"id":"db986c15-e106-5c64-bd3c-20222011a36b","slug":"basis-for-recommendation-d0a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 861a8f37-11f1-4b32-ae63-b303488cee43 --><h4>Basis for recommendation</h4><!-- end field 861a8f37-11f1-4b32-ae63-b303488cee43 -->","summary":null,"htmlStringContent":"<!-- begin item d0a076d3-2154-45ce-b956-93849a311a6c --><!-- begin field a1fea99f-7dc2-4849-9cad-de451f10f540 --><p>The recommendations on postpartum follow-up of women with gestational hypertension are largely based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</p><h5>Target blood pressure</h5><ul><li>NICE makes no explicit recommendations relating to target blood pressure in women with persisting gestational hypertension. CKS has therefore extrapolated NICE's advice for the postnatal management of women with chronic hypertension [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</li></ul><!-- end field a1fea99f-7dc2-4849-9cad-de451f10f540 --><!-- end item d0a076d3-2154-45ce-b956-93849a311a6c -->","subChapters":[]}]},{"id":"8e27adde-ead2-519b-a12a-11f2318c5b1b","slug":"follow-up-for-proteinuria-no-hypertension","fullItemName":"Follow-up for proteinuria and no hypertension","depth":3,"htmlHeader":"<!-- begin field 97488b65-2f74-410c-bab0-aae700b57a5a --><h3>How should I follow up a woman with proteinuria and no hypertension?</h3><!-- end field 97488b65-2f74-410c-bab0-aae700b57a5a -->","summary":null,"htmlStringContent":"<!-- begin item eba8b669-0992-4f32-9c05-aae700b57a0f --><!-- begin field e6ffe3fc-b8a8-4c4b-8ee7-aae700b57a5a --><ul><li><strong>At postnatal review 6–8 weeks after birth, for all women with unexplained isolated proteinuria during pregnancy who remained normotensive:</strong><ul><li>A urinary reagent-strip test should be carried out. Women with [1+] proteinuria should be offered a further review in primary care or by a specialist three months after delivery to assess kidney function.<ul><li>If this review takes place in primary care, assess renal function using estimated glomerular filtration rate (eGFR) and quantification of proteinuria.  For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>.</li><li>Consider referring women with an abnormal renal function assessment at 3 months for specialist assessment .</li></ul></li></ul></li></ul><!-- end field e6ffe3fc-b8a8-4c4b-8ee7-aae700b57a5a --><!-- end item eba8b669-0992-4f32-9c05-aae700b57a0f -->","subChapters":[{"id":"8073e5ad-baaa-58c4-9020-4e041b83ec48","slug":"basis-for-recommendation-92f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a471af39-d1f2-4d5f-8f5f-aae700b57a61 --><h4>Basis for recommendation</h4><!-- end field a471af39-d1f2-4d5f-8f5f-aae700b57a61 -->","summary":null,"htmlStringContent":"<!-- begin item 92f128db-82e1-4bd7-ba5f-aae700b57a61 --><!-- begin field c05e6357-36b1-4294-860b-aae700b57a61 --><p>In the absence of specific guidance from NICE relating to postpartum follow-up of women with proteinuria but no hypertension, CKS sought advice from a consultant obstetrician who advised that it is standard practice to continue monitoring proteinuria and if this persists, to consider seeking advice from a renal specialist depending on the urianry protein:creatinine ratio, as a proportion of women with these clinical signs will have underlying renal disease unrelated to pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Hodson, K, 2019,&nbsp;personal communication</a>]. The information about timing of follow-up and the specific assessments required at each time point was extrapolated from NICE's advice relating to postpartum monitoring of renal function in women with pre-eclampsia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>] .</p><!-- end field c05e6357-36b1-4294-860b-aae700b57a61 --><!-- end item 92f128db-82e1-4bd7-ba5f-aae700b57a61 -->","subChapters":[]}]},{"id":"91f2ab44-c607-59b3-b513-f09886817a42","slug":"suspected-postpartum-pre-eclampsia-or-eclampsia","fullItemName":"Suspected postpartum pre-eclampsia or eclampsia","depth":3,"htmlHeader":"<!-- begin field 0301fad7-b46e-40e1-b311-976d67f56d19 --><h3>How should I manage a woman with postpartum pre-eclampsia or eclampsia?</h3><!-- end field 0301fad7-b46e-40e1-b311-976d67f56d19 -->","summary":null,"htmlStringContent":"<!-- begin item 7271e0f9-cd7c-431a-aed3-30f4001cc81e --><!-- begin field 0107f237-da38-443b-849e-4db68581d04b --><ul><li><strong>All women with suspected postpartum pre-eclampsia or eclampsia should be admitted to hospital for immediate assessment.</strong></li><li>Consider the possibility of imminent pre-eclampsia or eclampsia in a woman up to 4 weeks postpartum (even if she has not had previous hypertension or pre-eclampsia) if she develops <em>any </em>of the following:<ul><li>Severe headaches (increasing frequency unrelieved by regular analgesics).</li><li>Visual problems, such as blurred vision, flashing lights, double vision, or floating spots.</li><li>Persistent new epigastric pain or pain in the right upper quadrant.</li><li>Vomiting.</li><li>Hypertension.</li><li>Proteinuria.</li><li>Breathlessness due to pulmonary oedema.</li><li>Sudden swelling of the face, hands, or feet.</li></ul></li><li>Consider the possibility of eclampsia in any woman who has a seizure within 4 weeks of delivery.</li></ul><!-- end field 0107f237-da38-443b-849e-4db68581d04b --><!-- end item 7271e0f9-cd7c-431a-aed3-30f4001cc81e -->","subChapters":[{"id":"14145fb5-337f-5a88-90b5-beb663b8f838","slug":"basis-for-recommendation-de2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field de303227-5997-40b8-9ec0-4e37a22c6f3d --><h4>Basis for recommendation</h4><!-- end field de303227-5997-40b8-9ec0-4e37a22c6f3d -->","summary":null,"htmlStringContent":"<!-- begin item de20ec96-23ad-495c-afeb-6a6be3f9e690 --><!-- begin field 5cf12705-4373-4d59-9518-a5e2027b431d --><h5>Symptoms of pre-eclampsia</h5><ul><li>The information on symptoms of pre-eclampsia is based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</li></ul><h5>Immediate admission to hospital</h5><ul><li>The recommendation to arrange hospital admission for women with suspected postpartum pre-eclampsia or eclampsia is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Importance of considering the possibility of pre-eclampsia or eclampsia even if no previous hypertension or pre-eclampsia</h5><ul><li>Pre-eclampsia and eclampsia may both present for the first time after delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Mathew et al, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Duley et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2015</a>].</li><li>A prospective descriptive study of every case of eclampsia in the UK in 2005-2006 found that 36% of cases occurred postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Knight and UKOSS, 2007</a>]. Because these cases were reported from obstetric units, this may have led to an underestimation of postpartum cases.</li></ul><h5>Possibility of pre-eclampsia or eclampsia up to 4 weeks postpartum</h5><ul><li>A multi-centre, retrospective analysis of data from 29 women with postpartum eclampsia found that 23 (79%) had late-onset eclampsia (developing more than 48 hours after delivery) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Chames et al, 2002</a>].</li><li>In a multi-centre, retrospective analysis that included 151 women readmitted to hospital with postpartum eclampsia, the average time from delivery to readmission was 7 days and ranged from 1–24 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Matthys et al, 2004</a>].</li></ul><h5>Possibility of pre-eclampsia or eclampsia if the woman develops typical symptoms</h5><ul><li>In a multi-centre, retrospective analysis of data from 89 women with eclampsia, 21/29 women with postpartum eclampsia had at least one prodromal symptom that heralded the onset of eclampsia: 20 women had headache, 10 women had vision changes, 5 women had nausea or vomiting, and 2 women had epigastric pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Chames et al, 2002</a>].</li><li>Case studies have shown that acute severe headache, vision disturbances, and gastrointestinal symptoms may herald impending postpartum eclampsia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Veltkamp et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Dziewas et al, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Mathew et al, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Graeber et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Munjuluri et al, 2005</a>].</li><li>A case-control study of 53 women admitted in the postpartum period found that headache, development of a blind spot, cortical blindness, malaise, nausea, and vomiting were more likely to occur in women with postpartum severe pre-eclampsia or eclampsia than in women with intrapartum pre-eclampsia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Atterbury et al, 1998</a>].</li></ul><h5>Possibility of eclampsia in any woman who has a seizure within 4 weeks postpartum</h5><ul><li>Case studies of three women report eclampsia developing without preceding hypertension or proteinuria up to four weeks after delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">Dziewas et al, 2002</a>].</li></ul><!-- end field 5cf12705-4373-4d59-9518-a5e2027b431d --><!-- end item de20ec96-23ad-495c-afeb-6a6be3f9e690 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}